Atomwise and Abe Heifets have joined forces to use AI in drug discovery. "We're especially excited to share this news because it strengthens our belief that AI is the industry standard in drug discovery. They will collaborate to test billions development targets selected by Eli Lilly . The partnership will use Atomwise ’s AI-driven structure-based small molecule drug discovery technology AtomNet, which is already being used in 19 countries. As part of the deal Atomwise could earn up to $550m for discovery milestones and up to $550m for milestones in development and commercialisation. CEO Atomwise said the technology could screen billions of compounds faster than existing screening systems, with up to 10,000 times greater accuracy.
Atomwise and Abe Heifets have joined forces to use AI in drug discovery. They will collaborate to test billions development targets selected by Eli Lilly . The partnership will use Atomwise ’s AI-driven structure-based small molecule drug discovery technology AtomNet, which is already being used in 19 countries. As part of the deal Atomwise could earn up to $550m for discovery milestones and up to $550m for milestones in development and commercialisation. CEO Atomwise said the technology could screen billions of compounds faster than existing screening systems, with up to 10,000 times greater accuracy.